Premier Research Names Dr. Colin Hayward as European Medical Director

PHILADELPHA, Jan. 16, 2012 /PRNewswire/ -- Premier Research Group announces the appointment of Dr. Colin Hayward to the position of European Medical Director. In this position, Dr. Hayward will be responsible for leading and developing the company's European medical affairs and pharmacovigilance operations, critical components of the company's global clinical development services offered to the biopharmaceutical industry.

"Dr. Hayward brings medical expertise, clinical knowledge, leadership, and a wealth of experience in key areas important to our customers and will provide an added level of therapeutic insight to Premier's services," said Dr. Sue Stansfield, Executive Vice President, Clinical Development.  "He will be a tremendous asset for both employees and customers and is a welcome addition to our strong team in Europe."

Dr. Hayward is a board certified pharmaceutical physician with 12 years international experience in pharmacovigilance, design and implementation of clinical programs and medical affairs. Before joining Roche pharmacovigilance and quickly progressing through a series of positions with increasing responsibility to International Medical Leader, Dr Hayward practiced in the UK Health Service in anaesthesia and intensive care. Most recently Dr Hayward was Director of Prism Ideas Ltd with responsibility for the medical team of this pharmaceutical medicine consultancy. Dr. Hayward attended the medical schools of Guys & St. Thomas's Hospitals in London.

About Premier Research
Premier Research is a professional services company providing clinical development support to the pharmaceutical, biotechnology, and medical device industries. Founded in 1989 and headquartered in Philadelphia, USA, the company has 21 offices across North America and Europe and operates in over 30 countries worldwide.  The company is a leader in performing clinical research in the analgesia, oncology, pediatrics, medical device and neurosciences areas. Additionally, it has grown a strong strategic sourcing group that supports customers in their resource planning and management.

The company offers a comprehensive series of services for every phase of clinical development including, regulatory affairs, clinical trial management, medical affairs and strategic consulting, pharmacovigilance, data operations, biostatistics, medical writing, interactive response technologies, and quality assurance.

For more information please visit, www.premier-research.com.

SOURCE Premier Research Group

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.